DR. JULIE ANNE DUNHILL, M.D.

BEVERLY HILLS, CA

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 1 publication 2017 – 2017 NPI: 1083610570
Internal Medicine - Hematology & Oncology
Heart FailureHeart-Assist DevicesBiomarkersHeart, ArtificialDown-RegulationVentricular Function, LeftProsthesis DesignProtein MultimerizationHemorrhagevon Willebrand Factor

Practice Location

9090 WILSHIRE BLVD
BEVERLY HILLS, CA 90211-1850

Phone: (310) 888-8680

What does JULIE DUNHILL research?

Dr. Dunhill studies how heart support devices, such as the left ventricular assist device (LVAD) and total artificial heart (TAH), influence the behavior of von Willebrand factor (VWF), a protein crucial for blood clotting. This research is vital for patients using these devices as it helps doctors manage their bleeding risks more effectively. By analyzing how these devices change VWF levels, Dr. Dunhill aims to provide insights that can improve treatment strategies for patients with severe heart conditions.

Key findings

  • Patients with a total artificial heart experienced a significant loss of the largest von Willebrand factor molecules.
  • Those with a left ventricular assist device showed varying degrees of von Willebrand factor loss, suggesting differing bleeding risks based on the device used.
  • Understanding the impact of these devices on VWF can help doctors better manage bleeding risks in heart patients.

Frequently asked questions

Does Dr. Dunhill study heart support devices?
Yes, Dr. Dunhill specifically researches how left ventricular assist devices and total artificial hearts affect blood clotting.
What treatments has Dr. Dunhill researched?
Dr. Dunhill's research focuses on heart support technologies, particularly the left ventricular assist device and total artificial heart.
Is Dr. Dunhill's work relevant to patients with bleeding disorders?
Yes, her insights on von Willebrand factor are particularly relevant for patients with bleeding risks associated with heart support devices.

Publications in plain English

Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart.

2017

Journal of thrombosis and haemostasis : JTH

Reich HJ, Morgan J, Arabia F, Czer L, Moriguchi J +5 more

Plain English
This study looked at how two different heart support devices—a left ventricular assist device (LVAD) and a total artificial heart (TAH)—affect a protein called von Willebrand factor (VWF), which plays a key role in blood clotting. The researchers found that all patients with TAH had a significant loss of the largest VWF molecules, while those with LVAD had varying degrees of loss, with some losing more than others. These findings are important because they show that the type of device used can lead to different bleeding risks, helping doctors better manage and treat patients who have these devices. Who this helps: This helps patients with LVADs and TAHs by improving understanding of their bleeding risks.

PubMed

Frequent Co-Authors

H J Reich J Morgan F Arabia L Czer J Moriguchi D Ramzy F Esmailian L Lam O Volod

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.